GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elite Pharmaceuticals Inc (STU:ETF) » Definitions » YoY EBITDA Growth

Elite Pharmaceuticals (STU:ETF) YoY EBITDA Growth : -100.00% (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Elite Pharmaceuticals YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Elite Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Dec. 2023 was -100.00%.

Elite Pharmaceuticals's EBITDA per Share for the three months ended in Dec. 2023 was €0.00.


Elite Pharmaceuticals YoY EBITDA Growth Historical Data

The historical data trend for Elite Pharmaceuticals's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elite Pharmaceuticals YoY EBITDA Growth Chart

Elite Pharmaceuticals Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -200.00 100.00 - 40.00 -14.29

Elite Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 50.00 -100.00 100.00 -200.00 -100.00

Elite Pharmaceuticals YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Elite Pharmaceuticals's YoY EBITDA Growth for the fiscal year that ended in Mar. 2023 is calculated as:

YoY EBITDA Growth (A: Mar. 2023 )
=(EBITDA per Share (A: Mar. 2023 )-EBITDA per Share (A: Mar. 2022 ))/ | EBITDA per Share (A: Mar. 2022 ) |
=(0.006-0.007)/ | 0.007 |
=-14.29 %

Elite Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (Q: Dec. 2023 )
=(EBITDA per Share (Q: Dec. 2023 )-EBITDA per Share (Q: Dec. 2022 )) / | EBITDA per Share (Q: Dec. 2022 )) |
=(0-0.003)/ | 0.003 |
=-100.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Elite Pharmaceuticals YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Elite Pharmaceuticals's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Elite Pharmaceuticals (STU:ETF) Business Description

Traded in Other Exchanges
Address
165 Ludlow Avenue, Northvale, NJ, USA, 07647
Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.

Elite Pharmaceuticals (STU:ETF) Headlines

No Headlines